Registration number: 04308175

Oxford Biomaterials Limited

Contents

Company Information	1
Balance Sheet	2
Notes to the Unaudited Financial Statements	3 to 6

Oxford Biomaterials Limited

Company Information

Director

Dr. F Vollrath

Registered office

Magdalen Centre Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA

Accountants

Carbon Accountancy Limited 80-83 Long Lane London EC1A 9ET

Oxford Biomaterials Limited

(Registration number: 04308175)
Balance Sheet as at 28 February 2025

	Note	2025 £	2024 £
Fixed assets
Tangible assets	4	-	88
Other financial assets	5	50,000	50,000
		50,000	50,088
Current assets
Debtors	6	186	13
Cash at bank and in hand		5,819	10,309
		6,005	10,322
Creditors: Amounts falling due within one year	7	(3,059)	(1,700)
Net current assets		2,946	8,622
Net assets		52,946	58,710
Capital and reserves
Called up share capital	8	1,809	1,809
Retained earnings		51,137	56,901
Shareholders' funds		52,946	58,710

For the financial year ending 28 February 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 28 November 2025
 

......................................... Dr. F Vollrath Director

Oxford Biomaterials Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025

1	General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Magdalen Centre
Oxford Science Park
Robert Robinson Avenue
Oxford
OX4 4GA

These financial statements were authorised for issue by the director on 28 November 2025.

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Computer equipment	25% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Oxford Biomaterials Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025 (continued)

2	Accounting policies (continued)

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3	Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2024 - 1).

4	Tangible assets

	Furniture, fittings and equipment  £	Total £
Cost or valuation
At 1 March 2024	1,057	1,057
At 28 February 2025	1,057	1,057
Depreciation
At 1 March 2024	969	969
Charge for the year	88	88
At 28 February 2025	1,057	1,057
Carrying amount
At 28 February 2025	-	-
At 29 February 2024	88	88

Oxford Biomaterials Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025 (continued)

5	Other financial assets (current and non-current)

	Financial assets at cost less impairment £	Total £
Non-current financial assets
Cost or valuation
At 1 March 2024	50,000	50,000
At 28 February 2025	50,000	50,000
Impairment
Carrying amount
At 28 February 2025	50,000	50,000

6

Debtors

Current	2025 £	2024 £
Other debtors	186	13
	186	13

7

Creditors

Creditors: amounts falling due within one year

	2025 £	2024 £
Due within one year
Trade creditors	1,059	-
Other creditors	2,000	1,700
	3,059	1,700

Oxford Biomaterials Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025 (continued)

8	Share capital

Allotted, called up and fully paid shares

	2025		2024
	No.	£	No.	£
Ordinary share capital of £0.01 each	180,919	1,809	180,919	1,809

9	Immediate parent undertaking

The company's immediate parent is Oxford Biomaterials Holdings Limited, incorporated in England and Wales.